Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    Contact Supplier

    Menu

    Oxaliplatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 34,039Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Onivyde Regimen Linked to Long-Term Survival in Pancreatic Cancer
    Onivyde Regimen Linked to Long-Term Survival in Pancreatic Cancer

    31 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/31/3091404/0/en/Late-breaking-analysis-demonstrates-characteristics-associated-with-long-term-overall-survival-with-Onivyde-regimen-in-metastatic-pancreatic-adenocarcinoma.html

    GLOBENEWSWIRE
    31 May 2025
    Share Share
    Pfizer’s Braftovi Combo Halves Death Risk In Colorectal Cancer
    Pfizer’s Braftovi Combo Halves Death Risk In Colorectal Cancer

    30 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250530872619/en/Pfizers-BRAFTOVI-Combination-Regimen-Cuts-the-Risk-of-Death-in-Half-for-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer

    BUSINESSWIRE
    30 May 2025
    Share Share
    Bold Therapeutics Presents Poster on BOLD-100 at AACR 2025
    Bold Therapeutics Presents Poster on BOLD-100 at AACR 2025

    30 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-presents-late-breaking-poster-on-bold-100s-unique-ability-to-mitigate-oxaliplatin-induced-peripheral-neuropathy-oipn-at-aacr-annual-meeting-2025-302442129.html

    PR NEWSWIRE
    30 Apr 2025
    Share Share
    Bold Therapeutics's BOLD-100 May Prevent Oxaliplatin Nerve Damage
    Bold Therapeutics's BOLD-100 May Prevent Oxaliplatin Nerve Damage

    28 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bold-therapeutics-announces-presentation-of-late-breaking-data-on-bold-100s-unique-ability-to-mitigate-oxaliplatin-induced-peripheral-neuropathy-oipn-302439701.html

    PR NEWSWIRE
    28 Apr 2025
    Share Share
    Pfizer angles Braftovi combo for full FDA approval
    Pfizer angles Braftovi combo for full FDA approval

    04 Feb 2025

    // PRESS RELEASE

    https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovir-combination-regimen-significantly

    PRESS RELEASE
    04 Feb 2025
    Share Share
    Oxaliplatin Europe Offers EU GMP Approved Cancer Drug Mfg
    Oxaliplatin Europe Offers EU GMP Approved Cancer Drug Mfg

    27 Jul 2024

    // PRESS RELEASE

    https://www.naprodgroup.com/propofol_europe.php

    PRESS RELEASE
    27 Jul 2024
    Share Share